Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT05636215RecruitingPhase 1/Phase 2
Testing a new HER2-targeted drug for advanced solid tumors
This early-phase study tests a new investigational drug (IBI354) in people with advanced or metastatic solid cancers that have HER2 changes. It’s mainly meant to find out how the drug works in the body and whether it’s safe enough to keep studying.
Randwick, New South WalesAges 18 years+ - NCT03891706RecruitingPhase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Guangzhou, GaungdongAges 18–70 - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07102004RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
BeijingAges 18 years+ - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT06782425RecruitingPhase 1
Cell therapy for advanced stomach cancer with Claudin18.2 protein
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Anyang, HenanAges 18–75 - NCT06563375RecruitingPhase 1
Testing NP-101 for advanced solid tumors
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT07372625RecruitingPhase 1
How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Denver, ColoradoAges 18 years+ - NCT06892379RecruitingPhase 1
Study of HS-20110 for advanced solid tumors
This trial is testing a new drug called HS-20110 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Tamarac, FloridaAges 18 years+ - NCT07300943RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
Boston, MassachusettsAges 18 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Sacramento, CaliforniaAges 18 years+ - NCT06365840RecruitingPhase 2
Study of IMC-001 for advanced tumors with high mutations
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
GoyangAges 19 years+ - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75 - NCT05906862RecruitingPhase 1
AMT-253 for advanced solid tumors after standard treatments
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
Sydney, New South WalesAges 18 years+ - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+ - NCT06985355RecruitingPhase 1/Phase 2
Testing MHB046C injection for advanced solid tumors
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT06487455RecruitingPhase 1
SPH7485 tablets for advanced solid tumors
This phase 1 trial tests a new oral drug called SPH7485 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
ChangshaAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,393 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.